Literature DB >> 17619525

Schizophrenia: a review.

Stephen H Schultz1, Stephen W North, Cleveland G Shields.   

Abstract

Schizophrenia is a debilitating mental illness that affects 1 percent of the population in all cultures. It affects equal numbers of men and women, but the onset is often later in women than in men. Schizophrenia is characterized by positive and negative symptoms. Positive symptoms include hallucinations, voices that converse with or about the patient, and delusions that are often paranoid. Negative symptoms include flattened affect, loss of a sense of pleasure, loss of will or drive, and social withdrawal. Both types of symptoms affect patients' families; therefore, it is important for physicians to provide guidance to all persons affected by the disease. Psychosocial and family interventions can improve outcomes. Medications can control symptoms, but virtually all antipsychotics have neurologic or physical side effects (e.g., weight gain, hypercholesterolemia, diabetes). There is a 10 percent lifetime risk of suicide in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17619525

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  44 in total

1.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

2.  Exploring schizophrenia drug-gene interactions through molecular network and pathway modeling.

Authors:  Daniel K Putnam; Jingchun Sun; Zhongming Zhao
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

Review 3.  Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

Authors:  Meng-Lin Li; Xi-Quan Hu; Feng Li; Wen-Jun Gao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-02-24       Impact factor: 5.067

4.  Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.

Authors:  Emilie Lauressergues; Bart Staels; Karine Valeille; Zouher Majd; Dean W Hum; Patrick Duriez; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-03-24       Impact factor: 3.000

5.  Pharmacological characterization of social isolation-induced hyperactivity.

Authors:  Katrine Fabricius; Lone Helboe; Anders Fink-Jensen; Gitta Wörtwein; Björn Steiniger-Brach
Journal:  Psychopharmacology (Berl)       Date:  2010-12-31       Impact factor: 4.530

6.  DNA methylation and expression profiles of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia.

Authors:  Dor Mohammad Kordi-Tamandani; Roya Sahranavard; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

7.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

Review 8.  DNA Damage in Major Psychiatric Diseases.

Authors:  Muhammad Ummear Raza; Turan Tufan; Yan Wang; Christopher Hill; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2016-04-28       Impact factor: 3.911

9.  The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.

Authors:  Hai Xia Zhang; Krzysztof Hyrc; Liu Lin Thio
Journal:  J Physiol       Date:  2009-05-11       Impact factor: 5.182

10.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.